TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma [Yahoo! Finance]
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
TuHURA Biosciences (NASDAQ:HURA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
TuHURA Biosciences (NASDAQ:HURA) had its "buy" rating reaffirmed by analysts at HC Wainwright.